key: cord-1041772-mrhrtwqr authors: El-Qutob, D.; Nieto, M.; Alvarez-Arroyo, L.; Carrera-Hueso, FJ title: Is there any effect of flu vaccine on the SARS-CoV-2 infected patients? date: 2021-11-04 journal: Vacunas DOI: 10.1016/j.vacun.2021.09.001 sha: 7c85f7e51733b8f4d73c8186511396affeaed924 doc_id: 1041772 cord_uid: mrhrtwqr Objectives: On 11 March, WHO declared a global pandemic caused by a new virus of the family Coronaviridae that has since been called SARS-CoV-2. COVID-19 does not have specific antiviral drug treatment currently. There are currently more than one hundred research projects into vaccines against SARS-CoV-2 worldwide, and 17 of them are already being tested on humans, according to the WHO. Until we have an effective vaccine, the possible preventive effect of flu vaccine for SARS-CoV-2 infection based on cross-reactivity has been postulated. Our objective was to analyze the effect of vaccination against flu virus in the season prior to the COVID-19 pandemic in our hospitalized SARS-CoV-2 infected patients. Methods: We performed a retrospective observational cohort study of patients admitted to hospital with SARS-CoV2 infection. We analyzed the differences between patients who had received or had not the flu vaccination for the 2019-2020 season. Results: We found no significant differences (p = 0.09) in patients who died (43 in total), of whom 23 (21.5%) were vaccinated against the flu and 20 (13.5%) were not. In mortality, we obtained an adjusted OR=0.873 (95% CI: 0.294 to 2.083), and about the success of health care the adjusted OR was 1.447 (95% CI: 0.610 to 3.430). Conclusions: Flu vaccination in patients admitted for SARS-CoV-2 infection had neither a beneficial nor a harmful effect on the clinical courses or outcomes of patients admitted to an European hospital. On 11 March, WHO declared a global pandemic caused by a new virus of the family Coronaviridae that has since been called SARS-CoV-2(1). COVID-19 does not have specific antiviral drug treatment currently, so the treatment of the disease is mainly focused on symptomatic treatment and oxygen therapy, although hundreds of clinical trials are being conducted (www.clinicaltrials.org). Therefore, the therapeutic attitude is empirical. Until we have an effective vaccine, the possible preventive effect of flu vaccine for SARS-CoV-2 infection based on cross-reactivity has been postulated (2) . Our objective was to analyze the effect of vaccination against flu virus in the season prior to the COVID-19 pandemic in our hospitalized SARS-CoV-2 infected patients. A retrospective observational cohort study enrolled patients 18 years of age or older admitted to hospital consecutively between 26 February and 20 May 2020, inclusive, with SARS-CoV2 infection confirmed by a real-time reverse transcription polymerase chain reaction (RT-PCR) diagnostic test on a nasopharyngeal aspirate or sputum sample. Due to false negatives in RT-PCR testing, a second diagnostic test was performed if infection was strongly suspected in view of patients' signs and symptoms and radiological examinations. With the result of the second test, the diagnosis was either confirmed or not confirmed. Patients with SARS-CoV-2 J o u r n a l P r e -p r o o f 5 5 infection who visited the accident and emergency department and were discharged home were not included in the study. Patients who declined to grant their informed consent to the SARS-CoV-2 infection treatments included in the protocol at our hospital were excluded from the study. Re-admitted patients were also excluded; only initial hospital admissions were included. Pregnant and breast-feeding women were excluded as well. The data collected from each patient, obtained from each patient's hospital electronic medical record, were demographic data, main comorbidities, clinical symptoms on admission, laboratory results, radiological tests and drug treatment. Patients' electronic records were consulted to confirm which of those patients admitted to our hospital during the COVID-19 pandemic had received the flu vaccination for the 2019-2020 season. Personal data were dissociated and pseudoanonymised in the database for subsequent statistical analysis by an independent expert. To obtain patients' survival data, patients were followed up until their discharge from hospital, transfer to another hospital or death. Patients' oxygen saturation on admission was measured using oxygen saturation measured by pulse oximetry/fraction of inspired oxygen (S/F) ratio. For proper interpretation, some variables were calculated categorised by CURB-65 score or short-form Charlson Comorbidity Index. Hospital care failure was considered to be patient death or ICU admission. A total of 255 patients were admitted to our hospital with a positive RT-PCR test during the study period. The characteristics of all our cohort has been published in other publication (3) . Of them, 42% (N = 107) received the flu vaccination in the prophylactic vaccine campaign for the 2019-2020 season in our country, 7 and 40 patients did not receive any type of vaccine. There was a preponderance of males (54.9%); this distribution was maintained in both study groups ( Table 1 ). The mean age of the patients was 68.4 (SD = 15.9) years, and was older in the group of vaccinated patients, who had a mean age of 79.5 years, than in the group of non-vaccinated patients, whose mean age was 60.7 years. As Table 1 shows, the comorbidities that were statistically significant between the two groups were: hypertension, diabetes, chronic obstructive Table 2 shows the results of the patients' laboratory tests on admission. The differences found were consistent with both groups' clinical conditions and comorbidities. Median respiratory function on admission, measured in terms of S/F ratio, was statistically better in non-vaccinated patients (383.72; IQR: 303.13-457.14) than in vaccinated patients (328.57; IQR: 230.00-447.62), although it had few clinical repercussions, since there were no differences with regard to need for noninvasive mechanical ventilation (p = 0.07). Patients' mean duration of admission was 12.1 (SD = 10.8) days, with no statistically significant differences between the two groups (p = 0.91); mean length of stay was 9 (5-15) days for vaccinated patients and 8 (5-16) days for non-vaccinated patients. There were also no differences between the two groups with regard to duration of ICU admission (p = 0.93). We found no significant differences (p = 0.09) with regard to patients who died (43 in total), of whom 23 (21.5%) were vaccinated against the flu and 20 (13.5%) were not. There were also no differences between the two groups when healthcare success was analysed (p = 0.21). Table 3 shows the odds ratios adjusted for the multivariate logistical analysis by the different covariates considered. It confirms that there were no significant differences on adjusting for said covariates in any of the endpoints considered. The median age of the vaccinated patients was much older (79.5 [71.5-85.0]) than the median age of the non-vaccinated patients (60.7 [49.1-75.1]), as Table 1 shows. This was because patients over 65 constitute a risk population for flu virus infection and, as a result, get the flu vaccine more often. In addition, the group of non-vaccinated patients had fewer comorbidities (80% with no comorbidities); this was probably linked to age. Nevertheless, despite this age difference, we did not observe any differences in outcomes for both patient groups in terms of either mortality rates or ICU admissions. We did, however, detect significant differences in initial symptoms presented by patients. Patients not vaccinated against the flu more often had dry cough, muscle pain, diarrhoea and headache; this difference was significant. Strikingly, non-vaccinated patients presented higher S/F ratio values, but showed no differences compared to vaccinated patients with regard to duration of ICU admission. Our study did not detect any influence on the part of the flu vaccine on the clinical course of patients admitted to hospital or on their morbidity or mortality rates. Possible biases that could act as confounding factors such as age and respiratory function status were controlled for by logistic regression, which found no relationship between flu vaccination and clinical course of SARS-CoV-2 infection (Table 3) Our study was not free from limitations, which should be borne in mind in evaluating it. First, its sample size and single-site nature, as well as its conduct within a specific healthcare system, may have induced a sample selection bias which would preclude translation to other situations and generalisation of its results. In addition, the data were collected and analysed retrospectively; a prospective study with a pre-data collection design should be conducted to determine causality relationships. Another limitation of the study was that it only enrolled patients in advanced stages of COVID-19 who required hospital admission and therefore excluded cases of milder and asymptomatic disease states. Finally, bias may have been introduced into our study, as in population-based studies, as data on patient vaccination was collected from centralised official registries. In conclusion, flu vaccination in patients admitted for SARS-CoV-2 infection had neither a beneficial nor a harmful effect on the clinical courses or outcomes of patients admitted to a European hospital. But taking in account other studies carried out in general population it seems that there is a flu vaccination protective effect for hospitalization. under which the difficulty of obtaining patients' consent would have compromised the conduct thereof. Study participants' personal data were processed in compliance with current European legislation. On behalf of all authors, the corresponding author states that there is no conflict of interest. WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19 Estudio descriptivo de una cohorte de pacientes COVID 19 hospitalizados en España Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil. medRxiv : the preprint server for health sciences Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19 CoV-2 infection and H1N1 vaccination: does a relationship between the two factors really exist? A retrospective analysis of a territorial cohort in Ferrara, Italy Effect of influenza vaccine on COVID-19 mortality: a retrospective study. Internal and emergency medicine Association between Exposure to Influenza Vaccination Glomerular filtration rate We acknowledge colleagues from our hospital who were on the front line of treatment of patients during the COVID-19 pandemic. They also contributed to the collection of necessary data to perform this study. We also want to thank the collaboration of Dr. Pilar Mañes from the Preventive Service of our hospital. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.